People: VIVUS Inc (VVUS.O)

Summary

Name	Age	Since	Current Position
Mark Logan	73	2007	Independent Chairman of the Board
Peter Tam	48	2009	President, Director
Leland Wilson	68	2009	Chief Executive Officer, Director
Timothy Morris	50	2012	Chief Financial Officer, Senior Vice President - Finance and Global Corporate Development, Secretary
Michael Miller	55	2010	Senior Vice President, Chief Commercial Officer
Guy Marsh	57	2000	Vice President - U.S. Operations, General Manager
Lee Perry	60	2007	Vice President, Chief Accounting Officer
Wesley Day	49	2005	Vice President - Clinical Development
John Slebir	46	2011	Vice President - Business Development, General Counsel
J. Martin Carroll		2013	Independent Director
Charles Casamento		2008	Independent Director
Ernest Mario	74	2012	Independent Director
Jorge Plutzky		2013	Independent Director
Linda Shortliffe	63	1999	Independent Director
Robert Wilson	72	2013	Independent Director
Brian Korb			IR Contact Officer

» Insider Trading

Biographies

Name	Description
Mark Logan	Mr. Mark B. Logan is Independent Chairman of the Board of Vivus, Inc., since April 2007. He has served as a director of the Company since March 1999. From November 1994 until his retirement in May 2001, Mr. Logan was Chairman of the Board, President and Chief Executive Officer of VISX, Inc., a medical device company. Mr. Logan also serves on the boards of STAAR Surgical Company, Gencia Corporation, the University of Virginia Heart & Vascular Center and serves as a trustee of the Southern Environmental Law Center. Mr. Logan holds a B.A. in Biology from Hiram College, was a Woodrow Wilson Fellow at New York University, and completed the P.M.D. Program at Harvard Business School.
Peter Tam	Mr. Peter Y. Tam is President, Director of Vivus, Inc., since October 2009. From January 2009 until October 2009, Mr. Tam served as Company's Chief Operating Officer. From July 2004 to January 2009, Mr. Tam served as Senior Vice President of Product and Corporate Development of the Company. From November 2002 to July 2004, Mr. Tam served as Company's Vice President of Strategic Planning and Corporate Development. Mr. Tam joined the Company in 1993 as Manager of Clinical Research and in 1999 he assumed the responsibilities of Director of Clinical and Corporate Development. Mr. Tam holds a B.S. in Chemistry from University of California Berkeley and an M.B.A. from Santa Clara University.
Leland Wilson	Mr. Leland F. Wilson is Chief Executive Officer, Director of Vivus, Inc., since November 1991. Mr. Wilson has served as a director since April 1991 and as Chief Executive Officer since November 1991. Mr. Wilson also served as President from April 1991 until October 2009. Prior to joining the Company, Mr. Wilson was Vice President of Marketing and Corporate Development of Genelabs Technologies, Inc. from 1989 to 1991. Mr. Wilson was Group Product Director, later promoted to Director of Marketing, at LifeScan, a Johnson & Johnson company, from 1986 to 1989. Mr. Wilson holds a B.S. and an M.S. in Reproductive Physiology from Pennsylvania State University.
Timothy Morris	Mr. Timothy E. Morris is Chief Financial Officer, Senior Vice President - Finance and Global Corporate Development, Secretary of Vivus, Inc. He joined VIVUS in November 2004. He currently serves as Company's Sr. Vice President Finance and Global Corporate Development, Chief Financial Officer and Secretary. In 2010, his title was changed to Sr. Vice President Finance, Chief Financial Officer. In February 2012, his role was expanded to include global corporate development responsibilities. From September 2001 to November 2004, Mr. Morris served as Chief Financial Officer and Senior Vice President of Finance & Administration at Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company. Mr. Morris holds a B.S. degree in Business with an emphasis in Accounting from California State University, Chico and is a certified public accountant.
Michael Miller	Mr. Michael P. Miller is Senior Vice President, Chief Commercial Officer of Vivus, Inc., since April, 2010. From February 2006 to April 2010, Mr. Miller served as a Vice President & Franchise Head of Genentech, Inc., a biotechnology company and wholly owned subsidiary of The Roche Group. From January 2003 to December 2005, Mr. Miller served as the Senior Vice President, Chief Commercial Officer of Connetics Corporation, a specialty pharmaceutical company acquired by Steifel Laboratories, Inc. Mr. Miller holds a B.S. in Business Administration and Finance from the University of San Francisco and an M.B.A. in Information and Computer Systems from San Francisco State University.
Guy Marsh	Mr. Guy P. Marsh is Vice President - U.S. Operations, General Manager of Vivus, Inc., since July 2000. In 2001, Mr. Marsh assumed responsibilities for U.S. Sales and Marketing of MUSE. Mr. Marsh holds a B.S. in Engineering from New Jersey Institute of Technology and an M.B.A. from Seton Hall University.
Lee Perry	Mr. Lee B. Perry is Vice President, Chief Accounting Officer of Vivus, Inc., since February 27, 2007. From March 2005 to February 2007, Mr. Perry served as the Company's Senior Director - Finance. From May 2002 to March 2005, Mr. Perry served as Senior Director - Finance at Questcor. Mr. Perry holds a B.A. in Economics from San Diego State University and is a certified public accountant.
Wesley Day	Dr. Wesley W. Day, Ph.D., is Vice President - Clinical Development of Vivus, Inc., since November 16, 2005. From September 2003 until October 2005, Dr. Day served as Senior Director—Safety and Risk Management at Pfizer Inc., a research-based global pharmaceutical company. Dr. Day holds a Ph.D. in Pharmacology and Toxicology from the University of Maryland at Baltimore and a B.S. from the University of Texas Pan American. Dr. Day is an Adjunct Associate Professor for the School of Pharmacy at the University of Maryland at Baltimore where he has held an adjunct appointment since 1995. He has also been an Adjunct Assistant Professor for Temple University in Philadelphia, Pennsylvania.
John Slebir	Mr. John L. Slebir, Esq., is Vice President - Business Development, General Counsel of Vivus, Inc. He has served as Company's General Counsel since September 2009 on a part-time basis. In January 2011, he was appointed to Vice President, General Counsel on a full-time basis. From March 1999 to January 2011, Mr. Slebir served as an attorney at Wilson Sonsini Goodrich & Rosati, P.C., specializing in corporate securities and corporate governance. Prior to joining Wilson Sonsini Goodrich & Rosati, P.C., Mr. Slebir was an attorney at two prominent Bay Area law firms specialized in insurance defense litigation. Mr. Slebir holds a B.A. in Communications from San Diego State University and a J.D. from Santa Clara University School of Law.
J. Martin Carroll	Mr. J. Martin Carroll has been appointed as Independent Director of VIVUS, Inc., effective May 10, 2013. From August 2002 through March 2013, Mr. Carroll served at Boehringer Ingelheim GmbH (BI), a pharmaceutical company, most recently as Head, Global Strategy and Development. After joining BI in August 2002, Mr. Carroll was appointed President and Chief Executive Officer of Boehringer Ingelheim US in January 2003 and served through 2011. From 1985 to 2001, Mr. Carroll served in various marketing, business development, sales and administrative positions at Merck & Co., Inc., a public pharmaceutical company. From 1984 to 1985, Mr. Carroll served as a Merck Executive on the President’s Commission on Executive Exchange at the United States Environmental Protection Agency. From 1976 to 1984, he served in various operational roles at Merck & Co., Inc. From 2004 to 2005, he served on the board of Accredo Health Group, Inc., a public company acquired by Medco Health Solutions, Inc., which provides specialty pharmacy and related services. Mr. Carroll holds a B.A. from Holy Cross College and a M.B.A. from Babson University.
Charles Casamento	Mr. Charles J. Casamento is Independent Director of Vivus, Inc., since April 17, 2008. Since May 2007, Mr. Casamento has been Executive Director and Principal of The Sage Group, Inc., a healthcare advisory group specializing in business development transactions. From October 2004 to April 2007, Mr. Casamento was President and Chief Executive Officer of Osteologix, Inc., a specialty pharmaceutical company. From 1999 until August 2004, he was the Chairman, Chief Executive Officer and President of Questcor Pharmaceuticals, a specialty pharmaceutical company. He currently also serves as a director of Cortex Pharmaceuticals, Inc., Astex, Inc., and International Stem Cell Corporation. Mr. Casamento holds a B.S. in Pharmacy from Fordham University and an M.B.A. from Iona College.
Ernest Mario	Dr. Ernest Mario, Ph.D., is Independent Director of Vivus, Inc., since April 18, 2012. Since August 2007, Dr. Mario has served as the Chief Executive Officer of Capnia, Inc., a privately held company focused on the development and commercialization of novel therapeutic and diagnostic products to address unmet healthcare needs. From January 1992 until March 1993, Dr. Mario served as Deputy Chairman of Glaxo Holdings plc., a pharmaceutical company, and as Chief Executive from May 1989 to March 1993. From November 1997 to December 2001, he served as Chairman and Chief Executive Officer of ALZA Corporation, a research-based pharmaceutical company providing drug delivery solutions, and Co-Chairman and Chief Executive Officer from August 1993 to November 1997. Dr. Mario has served as a director of Celgene, a biopharmaceutical company, since August 2007, Maxygen, Inc., a biotechnology company, since July 2001 and Boston Scientific Corporation, a developer, manufacturer and marketer of medical devices, since October 2001. From April 2003 to August 2007, Dr. Mario served as the Chairman of the Board and Chief Executive Officer of Reliant Pharmaceuticals, Inc., a privately held pharmaceutical company. He is Chairman of the American Foundation for Pharmaceutical Education and serves as an advisor to The Ernest Mario School of Pharmacy at Rutgers University. Dr. Mario is the recipient of the 2007 Remington Medal, the American Pharmacists Association's highest honor. Dr. Mario holds a B.S. in Pharmacy from Rutgers University, and a M.S. and a Ph.D. in Physical Sciences from the University of Rhode Island.
Jorge Plutzky	Dr. Jorge Plutzky, M.D., has been appointed as Independent Director of VIVUS, Inc., effective May 10, 2013. Since 1996, Dr. Plutzky has served as the Director of The Vascular Disease Prevention Program, which includes the Lipid/Prevention Clinic, in the Cardiovascular Medicine Division at Brigham and Women’s Hospital, where he is also Co-Director of Preventive Cardiology. Since 1995, he has been on the faculty at Harvard Medical School and has directed a basic science laboratory focused on transcriptional mechanisms involved in adipogenesis, lipid metabolism, and diabetes, and their relationship to inflammation and atherosclerosis. Throughout his career, Dr. Plutzky has also been involved in translational clinical studies investigating links between metabolic disorders and cardiovascular disease. Dr. Plutzky has been a member of the scientific advisory boards of the Sarnoff Cardiovascular Research Foundation since 2009 and Ember Therapeutics since 2012. Dr. Plutzky has been elected to the American Society for Clinical Investigation and is a Fellow of the American College of Cardiology. Dr. Plutzky has been involved with the U.S. Food and Drug Administration, serving both as a member of the Endocrinologic and Metabolic Drugs Advisory Committee and in advising and presenting for new drug application sponsors. He has been involved with both the American Heart Association and the American Diabetes Association. Dr. Plutzky has been recognized with the Eugene Braunwald Teaching Award, the University of Cologne’s Klenk Lecture, Vanderbilt University’s Rabin Lecture, Northwestern University’s DeStevens Lecture, and Harvard Medical School’s Tucker Collins Lecture. Dr. Plutzky holds a B.A. from the University of Virginia, where he was an Echols Scholar and a member of Phi Beta Kappa, and an M.D. from the University of North Carolina, Chapel Hill. He completed research fellowships at the National Institutes of Health and the Massachusetts Institute of Technology.
Linda Shortliffe	Dr. Linda M. Dairiki Shortliffe, M.D., is Independent Director of Vivus, Inc., since June 1999. Dr. Shortliffe has served as Professor of Urology at Stanford University School of Medicine since 1993 and was Chair of the Department of Urology from 1995 to 2011. She has been Chief of Pediatric Urology of Lucile Salter Packard Children's Hospital at Stanford since 1991. She is a Fellow of the American College of Surgeons and the American Academy of Pediatrics and is a past Trustee and President of the American Board of Urology. Dr. Shortliffe holds an A.B. from Radcliffe/Harvard College and an M.D. from Stanford University.
Robert Wilson	Mr. Robert N. Wilson is Independent Director of VIVUS, Inc. He is chairman of Mevion Medical Systems and former vice chairman of the Board of Directors of Johnson & Johnson. Mr. Wilson served in several roles at Johnson & Johnson, including the Executive Committee from 1983 through 2003 and vice chairman of the Board of Directors from 1988 through 2003. Mr. Wilson played a key role in the rapid growth of the pharmaceutical, device and diagnostic businesses within Johnson & Johnson. Mr. Wilson was also chairman of Caxton Health Holdings from 2004 through 2007, focusing on pharmaceutical and health technology investments. Mr. Wilson is also a director of Hess Corporation, an explorer and producer of oil and gas, the Charles Schwab Corporation, a financial services company, and Synta Pharmaceuticals, a research-based pharmaceutical company with a focus in cancer therapies.
Brian Korb

Basic Compensation

Name	Fiscal Year Total
Mark Logan	--
Peter Tam	1,326,790
Leland Wilson	2,353,660
Timothy Morris	1,042,930
Michael Miller	803,595
Guy Marsh	929,807
Lee Perry	--
Wesley Day	771,203
John Slebir	1,439,620
J. Martin Carroll	--
Charles Casamento	--
Ernest Mario	--
Jorge Plutzky	--
Linda Shortliffe	--
Robert Wilson	--
Brian Korb	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Mark Logan	0	0
Peter Tam	323,750	31,594
Leland Wilson	1,500,313	888,972
Timothy Morris	230,608	237,126
Michael Miller	0	0
Guy Marsh	499,255	800,521
Lee Perry	0	0
Wesley Day	23,442	154,969
John Slebir	0	0
J. Martin Carroll	0	0
Charles Casamento	0	0
Ernest Mario	0	0
Jorge Plutzky	0	0
Linda Shortliffe	0	0
Robert Wilson	0	0
Brian Korb	0	0

Insider Trading

Name	Shares Traded	Price
PLUTZKY JORGE	20,000	$0.00
CARROLL J MARTIN	20,000	$0.00
WILSON LELAND F	20,000	$0.00
MARIO ERNEST B	21,125	$0.00
CASAMENTO CHARLES J	21,125	$0.00
LOGAN MARK B	21,125	$0.00
DAIRIKI SHORTLIFFE LINDA M	21,125	$0.00
CASAMENTO CHARLES J	8,000	$20.63
CASAMENTO CHARLES J	8,000	$5.69
MARIO ERNEST B	5,000	$20.75
DAIRIKI SHORTLIFFE LINDA M	8,000	$5.04
LOGAN MARK B	8,000	$7.15
LOGAN MARK B	11,816	$23.13
DAIRIKI SHORTLIFFE LINDA M	8,000	$23.00
LOGAN MARK B	22,000	$6.05
LOGAN MARK B	22,000	$23.13
LOGAN MARK B	8,000	$23.13
LOGAN MARK B	11,816	$4.25
DAIRIKI SHORTLIFFE LINDA M	10,000	$4.25
LOGAN MARK B	8,000	$23.13
DAIRIKI SHORTLIFFE LINDA M	10,000	$22.50
LOGAN MARK B	8,000	$5.04
DAIRIKI SHORTLIFFE LINDA M	20,000	$22.00
DAIRIKI SHORTLIFFE LINDA M	20,000	$4.25
LOGAN MARK B	18,184	$4.25

» Full list on Insider Trading

People: VIVUS Inc (VVUS.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: